BCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Dec. 2023, BioCryst Pharmaceuticals paid $0.0 Mil more to buy back shares than it received from issuing new shares. It spent $1.2 Mil paying down its debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It spent $2.0 Mil on other financial activities. In all, BioCryst Pharmaceuticals spent $3.2 Mil on financial activities for the three months ended in Dec. 2023.
The historical data trend for BioCryst Pharmaceuticals's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 99.10 | 300.59 | 359.67 | 88.03 | 32.49 |
BioCryst Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Flow from Financing | Get a 7-Day Free Trial | 4.20 | 5.08 | 29.36 | 1.23 | -3.17 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
BioCryst Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0.342 | + | 0 | + | 58.383 | + | 0 | + | 0 | + | -26.24 |
= | 32.5 |
BioCryst Pharmaceuticals's Cash from Financing for the quarter that ended in Dec. 2023 is:
Cash Flow from Financing | (Q: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | 0 | + | -1.165 | + | 0 | + | 0 | + | -2.008 |
= | -3.2 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals (NAS:BCRX) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
BioCryst Pharmaceuticals's issuance of stock for the three months ended in Dec. 2023 was $0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
BioCryst Pharmaceuticals's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
BioCryst Pharmaceuticals's net issuance of debt for the three months ended in Dec. 2023 was $-1.2 Mil. BioCryst Pharmaceuticals spent $1.2 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
BioCryst Pharmaceuticals's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. BioCryst Pharmaceuticals paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
BioCryst Pharmaceuticals's cash flow for dividends for the three months ended in Dec. 2023 was $0.0 Mil. BioCryst Pharmaceuticals received $0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
BioCryst Pharmaceuticals's other financing for the three months ended in Dec. 2023 was $-2.0 Mil. BioCryst Pharmaceuticals spent $2.0 Mil on other financial activities.
Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Machelle Sanders | director | C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560 |
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Helen M. Thackray | director | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
Jon P Stonehouse | director, officer: CEO | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
Charles K Gayer | officer: Vice President and CCO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Michael L Jones | officer: Exec Director, Finance - PAO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Alane P Barnes | officer: VP, General Counsel & Corp Sec | 1929 BRASSFIELD ROAD, RALEIGH NC 27614 |
Anthony Doyle | officer: Chief Financial Officer | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Yarlagadda S Babu | officer: VP Drug Discovery | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
George B Abercrombie | director | C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
William P Sheridan | officer: SR VP - CMO | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
Vincent Milano | director | C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
Amy E Mckee | director | 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
Lee Kenneth B Jr | director | 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4 |
Steven K Galson | director | C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
From GuruFocus
By sperokesalga sperokesalga • 06-01-2023
By sperokesalga sperokesalga • 02-24-2023
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 07-17-2023
By sperokesalga sperokesalga • 02-22-2023
By Marketwired • 10-20-2023
By Marketwired • 07-19-2023
By sperokesalga sperokesalga • 05-04-2023
By PRNewswire PRNewswire • 05-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.